Clinical Trials Directory

Trials / Completed

CompletedNCT05070754

Cold Atmospheric Plasma Device for Pediatric Molluscum and Verruca

Using a Cold Atmospheric Plasma Device to Treat Molluscum Contagiosum and Verruca Vulgaris in Pediatric Patients

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
17 (actual)
Sponsor
Medical University of South Carolina · Academic / Other
Sex
All
Age
4 Years – 21 Years
Healthy volunteers
Not accepted

Summary

This study is going to test a cold atmospheric plasma device (CAP), in particular a floating electrode-dielectric barrier device (FE-DBD), to treat warts and molluscum. The treatment device in this study generates cold atmospheric plasma (gaseous ionized molecules) to rid the virus from the body. Based on the successes of previous dermatologic studies, FE-DBD is being tested for this study to treat warts and molluscum. Patients will be enrolled to test the efficacy and safety of this device. The duration of the study is 4-12 weeks depending on treatment clearance. The number of lesions will be chosen by the dermatologist. Patients will receive standard of care therapy and/or NTAP depending on the number of lesions.

Conditions

Interventions

TypeNameDescription
DEVICEFloating electrode-dielectric barrier device (FE-DBD) cold atmospheric plasma (CAP)The treatment device in this study generates cold atmospheric plasma. Cold atmospheric plasma has certain properties of plasma, such as ionized gas molecules. To create plasma, a pulse generator supplying 20 kilovolt pulse of 20-ns pulse width at 200 Hz (FPG10-01NM10, FID GmbH, Burbach, Germany) to a 5-mm diameter quartz-covered copper electrode of 10-cm length and 1 - 13mm quartz thickness. These nanosecond pulse parameters were chosen to provide sufficient treatment dose at the high level of plasma uniformity required to avoid any tissue damage. We will treat the lesions for approximately 1 to 2 minutes each, moving the electrode gently over the treatment area.
DEVICECryotherapyCryotherapy refers to the application of liquid nitrogen using a cryospray device in order to freeze a lesion of interest. Treatment is repeated every few weeks until the lesion of interest has disappeared. It is considered SOC for the treatment of warts.
DRUGCanthardin CollodionChemical compound that acts as a vesicant to form a blister around treatment area. The blister lifts the lesion of interest away from the skin, causing it to slough off in a few days. It is used as SOC for the treatment of Molluscum Contagiosum.

Timeline

Start date
2021-12-02
Primary completion
2022-12-31
Completion
2022-12-31
First posted
2021-10-07
Last updated
2024-04-05
Results posted
2024-04-05

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT05070754. Inclusion in this directory is not an endorsement.